Olanzapine-induced hyperglycemic ketoacidosis and corresponding acetone concentrations post-mortem: A forensic interpretation

Forensic Science International

Volumn 171, Issue 1, 2007, Pages 22-26

  House, Chris J ^a  

^a Ministry of Community Safety and Correctional Services Centre of Forensic Sciences   (Canada)

Author keywords

Acetone; Diabetes; Ketoacidosis; Olanzapine

Indexed keywords

ACETONE; GLUCOSE; KETONE; OLANZAPINE;

ARTICLE; AUTOPSY; DRUG BLOOD LEVEL; DRUG DETERMINATION; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERGLYCEMIC KETOACIDOSIS; KETOACIDOSIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SCREENING; TOXICITY TESTING;

EID: 34547468926     PISSN: 03790738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.forsciint.2006.09.009     Document Type: Article

References (35)

1. Spivak B., Alamy S.S., Jarskog L.F., Sheitman B.B., and Lieberman J.A. Ziprasidone alternative for olanzapine-induced hyperglycemia. Am. J. Psychol. 159 (2002) 1606
2. Avella J., Wetli C.V., Wilson J.C., Katz M., and Hahn T. Fatal olanzapine-induced hyperglycemic ketoacidosis. Am. J. Forensic Med. Pathol. 25 (2004) 172-175
3. Henderson D.C., Cagliero E., Copeland P.M., Borba C.P., Evins E., Hayden D., Weber M.T., Anderson E.J., Allison D.B., Daley T.B., Schoenfeld D., and Goff D.C. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch. Gen. Psychol. 62 (2005) 19-28
4. Leslie D.L., and Rosenheck R.A. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am. J. Psychol. 161 (2004) 1709-1711
5. Farwell W.R., Stump T.E., Wang J., Tafesse E., L'Italien G., and Tierney W.M. Weight gain and new onset diabetes associated with olanzapine and risperidone. J. Gen. Int. Med. 19 (2004) 1200-1205
6. Johnson R.P., Al-Taher M.T., Madlock L.E., Guo M., and Nasdahl C.S. Increasing insulin dose for olanzapine-related diabetes. Am. J. Psychol. 159 (2002) 150-151
7. Meatherall R., and Younes J. Fatality from olanzapine induced hyperglycemia. J. Forensic Sci. 47 (2002) 893-896
8. Torrey E.F., and Swalwell C.I. Fatal olanzapine-induced ketoacidosis. Am. J. Psychol. 160 (2003) 2241
9. Koller E.A., and Doraiswamy P.M. Olanzapine-associated diabetes mellitus. Pharmacotherapy 22 (2002) 841-852
10. Graham K.A., Perkins D.O., Edwards L.J., Barrier Jr. R.C., Lieberman J.A., and Harp J.B. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am. J. Psychol. 162 (2005) 118-123
11. Lambert B.L., Chang K.Y., Tafesse E., and Carson W. Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia. J. Clin. Psychopharm. 25 (2005) 12-18
12. Koves E.M., and Wells J. An evaluation of fused silica capillary columns for the screening of basic drugs in post-mortem blood: qualitative and quantitative analysis. J. Forensic Sci. 30 (1985) 692-707
13. Machata G. Determination of alcohol in blood by gas chromatography head space analysis. Clin. Chem. News 4 (1972) 29-32
14. Robertson M.D., and McMullin M.M. Olanzapine concentrations in clinical serum and post-mortem blood specimens-when does therapeutic become toxic?. J. Forensic Sci. 45 (2000) 418-421
15. Perry P.J., Sanger T., and Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J. Clin. Psychopharm. 17 (1997) 472-477
16. Aravagiri M., Ames D., Wirshing W.C., and Marder S.R. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection. Ther. Drug Mon. 19 (1997) 307-313
17. Bergemann N., Frick A., Parzer P., and Kopitz J. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychology 37 (2004) 63-68
18. Crookham S.B., Diamond F.X., Davis P.J., and Reiber T.M. Development of a gas chromatographic method for the determination of olanzapine in human serum and a report of patient values. Clin. Chem. 44 (1998) A103
19. Harrigan E.P., Miceli J.J., Anziano R., Watsky E., Reeves K.R., Cutler N.R., Sramek J., Shiovitz T., and Middle M. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J. Clin. Psychopharm. 24 (2004) 62-69
20. Hiemke C., Peled A., Jabarin M., Hadjez J., Weigmann H., Hartter S., Modai I., Ritsner M., and Silver H. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J. Clin. Psychopharm. 22 (2002) 502-506
21. Jenkins A.J., Sarconi K.M., and Raaf H.N. Determination of olanzapine in a post-mortem case. J. Anal. Toxicol. 22 (1998) 605-609
22. B.S. Levine, S.C. Wu, J.E. Smialek, Olanzapine concentrations in forensic investigations, in: J.R. Monforte (Ed.) Tox Talk, Abstracts of Joint Meeting for Society of Forensic Toxicologists and International Association of Forensic Toxicology, Society of Forensic Toxicologists, Mesa Az, 1998, pp. 114.
23. S.H.Y. Wong, S.B. Gock, S.E. Venuti, A. Stormo, J. Greenbaum, L. Biedrzycki, J.M. Jentzen, Olanzapine associated deaths: a report of five cases, in: J.R. Monforte (Ed.) Tox Talk, Abstracts of Joint Meeting for Society of Forensic Toxicologists and International Association of Forensic Toxicology, Society of Forensic Toxicologists, Mesa Az, 1998, pp. 115.
24. Merrick T.C., Felo J.A., and Jenkins A.J. Tissue distribution of olanzapine in a postmortem case. Am. J. Forensic Med. Path. 22 (2001) 270-274
25. Gerber J.E., and Cawthon B. Overdose and death with olanzapine. Two case reports. Am. J. Forensic Med. Path. 21 (2000) 249-251
26. Stephens B.G., Coleman D.E., and Baselt R.C. Olanzapine-related fatality. J. Forensic Sci. 43 (1998) 1252-1253
27. Horak E.L., and Jenkins A.J. Postmortem tissue distribution of olanzapine and citalopram in a drug intoxication. J. Forensic Sci. 50 (2005) 679-681
28. Elian A.A. Fatal overdose of olanzapine. Forensic Sci. Int. 91 (1998) 231-235
29. D.T. Anderson, T. Kuwahara, Thirty-five case studies involving post-mortem tissue distributions of olanzapine (Zyprexa), in: J.R. Monforte (Ed.) Tox Talk, Abstracts of Joint Meeting for Society of Forensic Toxicologists and International Association of Forensic Toxicology, Society of Forensic Toxicologists, Mesa Az, 1998, pp. 113.
30. Lakso H.A. Instability of olanzapine in calf serum. Ther. Drug Mon. 23 (2001) 454-455
31. Jones A.W., Sagarduy A., Ericsson E., and Arnqvist H.J. Concentrations of acetone in venous blood samples from drunk drivers, type-1 diabetic outpatients, and healthy blood doners. J. Anal. Toxicol. 17 (1993) 182-185
32. Brinkmann B., Fechner G., Karger B., and DuChesne A. Ketoacidosis and lactic acidosis-frequent causes of death in chronic alcoholics?. Int. J. Legal Med. 111 (1998) 115-119
33. M.F. Mason, D. Hutson, The range of concentrations of free acetone in the plasma and breath of diabetics and some observations on its plasma/breath ratio, in: S. Israelstam, S. Lambert (Eds.), Proceedings of the Sixth International Conference on Alcohol, Drugs, and Traffic Safety, Toronto, Ontario, 1975, pp. 533-539.
34. OStbye T., Curtis L.H., Masselink L.E., Hutchison S., Wright A., Dans P.E., Schulman K.A., and Krishnan R.R. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. Pharmacoepid. Drug Safety 14 (2005) 407-415
35. Sacchetti E., Turrina C., Parrinello G., Brignoli O., Stefanini G., and Mazzaglia G. Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure. Int. Clin. Psychopharmacol. 20 (2005) 33-37